Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in: The European Journal of Health Economics 5/2011

01.10.2011 | Original Paper

Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients

verfasst von: C. Sabariego, M. Brach, P. Herschbach, P. Berg, G. Stucki

Erschienen in: The European Journal of Health Economics | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Anxiety and fear are often associated with chronic conditions such as cancer. This paper targets the cost-effectiveness analysis of a cognitive-behavioral group therapy (CBT) in comparison to a client-centered, supportive-experiential group therapy (SET) in cancer patients with dysfunctional fear of progression. An incremental cost-effectiveness analysis was performed using data from a randomized controlled trial among cancer patients receiving inpatient rehabilitation. The means, 95% confidence intervals [95% CI], incremental cost-effectiveness graphic and acceptability curve were obtained from 1,000 bootstrap replications. A total of 174 patients were included in the economic evaluation. The estimated means [95% CI] of direct costs and reduction of fear of progression were €9,045.03 [6,359.07; 12,091.87] and 1.41 [0.93; 1.92] for patients in the SET and €6,682.78 [4,998.09; 8,440.95] and 1.44 [1.02; 1.09] for patients in the CBT. The incremental cost-effectiveness ratio [95% CI] amounts to minus €78,741.66 [−154,987.20; 110,486.32] for an additional unit of effect. Given the acceptability curve, there is a 92.4% chance that the CBT, compared with the SET, is cost-effective without the need of additional costs to payers. Our main result is the superior cost-effectiveness of the cognitive-behavioral intervention program in comparison to the non-directive encounter group for our sample of cancer patients with high levels of anxiety.
Literatur
1.
Hoffman, D.L., Dukes, E.M., Wittchen, H.U.: Human and economic burden of generalized anxiety disorder. Depress Anxiety, 1091–4269 (2006)
2.
Andlin-Sobocki, P., Wittchen, H.U.: Cost of anxiety disorders in Europe. Eur. J. Neurol. 12(Suppl 1), 39–44 (2005)PubMedCrossRef
3.
Wittchen, H.U.: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16, 162–171 (2002)PubMedCrossRef
4.
Herschbach, P., Berg, P., Dankert, A., Duran, G., Engst-Hastreiter, U., Waadt, S., Keller, M., Ukat, R., Henrich, G.: Fear of progression in chronic diseases: psychometric properties of the fear of progression questionnaire. J. Psychsom. Res. 58, 505–511 (2005)CrossRef
5.
Sheard, T., Maguire, P.: The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br. J. Cancer 80, 1770–1780 (1999)PubMedCrossRef
6.
Meyer, T.J., Mark, M.M.: Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol. 14, 101–108 (1995)PubMedCrossRef
7.
Newell, S.A., Sanson-Fisher, R.W., Savolainen, N.J.: Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J. Natl Cancer Inst. 94, 558–584 (2002)PubMed
8.
Owen, J.E., Klapow, J.C., Hicken, B., Tucker, D.C.: Psychosocial interventions for cancer: review and analysis using a three-tiered outcomes model. Psychooncology 10, 218–230 (2001)PubMedCrossRef
9.
Herschbach, P., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G., Book, K., Dinkel, A.: Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother. Psychosom. 79, 31–38 (2010)PubMedCrossRef
10.
Herschbach, P., Book, K., Dinkel, A., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter, U., Henrich, G.: Evaluation of two group therapies to reduce fear of progression in cancer patients. Support. Care Cancer 18, 471–479 (2010)PubMedCrossRef
11.
Rosenberg, H.J., Rosenberg, S.D., Ernstoff, M.S., Wolford, G.L., Amdur, R.J., Elshamy, M.R., Bauer-Wu, S.M., Ahles, T.A., Pennebaker, J.W.: Expressive disclosure and health outcomes in a prostate cancer population. Int. J. Psychiatry Med. 32, 37–53 (2002)PubMedCrossRef
12.
Simpson, J.S., Carlson, L.E., Trew, M.E.: Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 9, 19–26 (2001)PubMedCrossRef
13.
Mehnert, A., Herschbach, P., Berg, P., Henrich, G., Koch, U.: Fear of progression in breast cancer patients—validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF). Z. Psychosom. Med. Psychother. 52, 274–288 (2006)PubMed
14.
Herschbach, P., Duran, G., Engst-Rastreiter, U., Waadt, S., Berg, P.: Gruppentherapetische Behandlung von Progredienzangst bei Krebspatienten. Verhaltenstherapie Verhaltensmedizin 27, 298–309 (2006)
15.
Hessel, F., Wittman, M., Petro, W., Wasem, J.: Methoden zur Kostenerfassungim Rahmen der ökonomischen Evaluation einer Rehabilitations-maßnahme bei chronischen Atemwegserkrankungen. Pneumologie 54, 289–295 (2002)CrossRef
16.
Rote-Liste: Rote Liste Service GmbH. In: ECV Verlag, Frankfurt (2004)
17.
AOK: Vergütungsliste für Orthopädische Hilfsmittel der Primärkassen in Bayern (2004)
18.
Krauth, C., Hessel, F., Hansmeier, T., Wasem, J., Seitz, R., Schweikert, B.: Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67, 736–746 (2005)PubMedCrossRef
19.
Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., Sullivan, M.: Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessment. J. Clin. Epidemiol. 51, 1171–1178 (1998)PubMedCrossRef
20.
Barber, J.A., Thompson, S.G.: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat. Med. 19, 3219–3236 (2000)PubMedCrossRef
21.
Carpenter, J., Bithell, J.: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat. Med. 19, 1141–1164 (2000)PubMedCrossRef
22.
Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford Medical Publications, New York (1997)
23.
Briggs, A.H.: Statistical approaches to handling uncertainty in health economic evaluation. Eur. J. Gastroenterol. Hepatol. 16, 551–561 (2004)PubMedCrossRef
24.
Chiles, J.A., Lambert, M.J., Michael, J., Hatch Arlin, L.: The impact of psychological interventions on medical cost offset: a meta-analytic review. Clin. Psychol. Sci. Prax. 6, 204–220 (1999)CrossRef
25.
Knapp, M., Thorgrimsen, L., Patel, A., Spector, A., Hallam, A., Woods, B., Orrell, M.: Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br. J. Psychiatry 188, 574–580 (2006)PubMedCrossRef
26.
Briggs, A.: Economic evaluation and clinical trials: size matters. BMJ 321, 1362–1363 (2000)PubMedCrossRef
27.
Briggs, A., Fenn, P.: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7, 723–740 (1998)PubMedCrossRef
28.
Fenwick, E., O’Brien, B.J., Briggs, A.: Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 13, 405–415 (2004)PubMedCrossRef
29.
Heuzenroeder, L., Donnelly, M., Haby, M.M., Mihalopoulos, C., Rossell, R., Carter, R., Andrews, G., Vos, T.: Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. N. Z. J. Psychiatry 38, 602–612 (2004)PubMedCrossRef
30.
Chuang, L.H., Kind, P.: Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics 27, 491–505 (2009)PubMedCrossRef
Metadaten
Titel
Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients
verfasst von
C. Sabariego
M. Brach
P. Herschbach
P. Berg
G. Stucki
Publikationsdatum
01.10.2011
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 5/2011
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0266-y

Weitere Artikel der Ausgabe 5/2011

The European Journal of Health Economics 5/2011 Zur Ausgabe

Original Paper

Contractual conditions, working conditions and their impact on health and well-being

Original paper

Atrial fibrillation: the cost of illness in Sweden

Original Paper

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor

Original Paper

Hospital’s activity-based financing system and manager: physician interaction

Original Paper

Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals

Original Paper

Ageing and health care expenditure in EU-15